Follow my blog with Bloglovin
Saturday , 24 August 2019
Breaking News

PureTech Acquires New Clinical-Stage Program LYT-100 to Treat Lymphedema

Wholly owned program adds to Company’s growing internal pipeline focused on lymphatic targeting and tissue-selective immunomodulation

Clinical proof-of-concept study in adults with secondary lymphedema planned for 2020

BOSTON-PureTech Health plc (LSE: PRTC) (“PureTech”), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced it has acquired and plans to develop a clinical-stage product candidate for the potential treatment of lymphatic and immunofibrotic diseases, including lymphedema. In preclinical studies, the oral, small molecule candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms, and in a Phase 1 clinical trial in healthy volunteers, LYT-100 was observed to be well tolerated with a favorable pharmacokinetic profile to support twice daily oral dosing. LYT-100 expands PureTech’s internal R&D pipeline and continues its progress in developing new medicines based on insights into the lymphatic system and local modulation of the immune system for the treatment of immune and central nervous system disorders, lymphatic conditions, and cancers.

“Lymphedema is a chronic and incurable secondary disease affecting millions of people, and there has been far too little progress made toward the development of meaningful treatments,” said Joe Bolen, Ph.D., chief scientific officer of PureTech. “There are no approved drug therapies on the market that can treat lymphedema. PureTech is working to address this need by pioneering an approach designed to target the underlying fibrosis and inflammation affecting the lymphatics to potentially improve lymphatic function and decrease the symptoms of lymphedema. We look forward to advancing clinical studies and continuing to progress the development of this candidate.”

Lymphedema is one of the most common lymphatic diseases. It is a chronic condition that afflicts millions of people and is characterized by severe swelling in parts of the body – usually in the arms or legs – due to the build-up of lymph fluid and inflammation, fibrosis, and adipose deposition. The most prevalent form of the condition, secondary lymphedema, is frequently caused by cancer treatments or infections resulting in damage to or the removal of lymph nodes. For example, of the more than 250,000 Americans diagnosed with breast cancer each year, up to one in five who receive surgery will develop secondary lymphedema. The current standards of care for lymphedema – compression and physical therapy – are cumbersome and non-curative approaches that cannot correct immune cell infiltration or regenerate the dysregulated lymphatics. If left untreated, lymphedema can lead to disfigurement, severe pain, disability, infection, and fibrosis. PureTech’s product candidate, LYT-100, has the potential to fulfill a widespread need for an effective approach that can treat secondary lymphedema without surgery.

“PureTech is committed to developing a long-awaited treatment for the millions of people living with lymphedema,” said Daphne Zohar, co-founder and chief executive officer of PureTech. “LYT-100 was identified for our internal pipeline through our expertise in the lymphatic system, and it is the first clinical candidate to advance from an ongoing sourcing effort that builds on insights from our team and our network of collaborators and key opinion leaders in the field. We also expect to advance other candidates in pilot clinical studies, and we will progress the ones with the most favorable clinical profile.”

LYT-100, an oral small molecule with well-established preclinical anti-fibrotic activity, has been previously studied in healthy volunteers as part of a Phase 1, single ascending dose study. PureTech will continue clinical development in healthy volunteers, looking at additional safety and pharmacokinetics of LYT-100 prior to initiating a human biomarker and proof-of-concept study expected in 2020. LYT-100 was acquired from a large pharmaceutical company where it was originally being developed in another indication.

Comments are closed.

Scroll To Top
badge